美国工商五金公司(CMC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CMC 美国工商五金公司

交易中 05-10 15:29:33 EDT

57.29

-0.26

-0.45%

最高57.97	最低57.25	成交量25.69万
今开57.97	昨收57.55	日振幅1.25%
总市值66.29亿	流通市值65.71亿	总股本1.16亿
成交额1,477万	换手率0.22%	流通股本1.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"CMC","market":"US","secType":"STK","nameCN":"美国工商五金公司","latestPrice":57.29,"timestamp":1715369364572,"preClose":57.55,"halted":0,"volume":256923,"delay":0,"floatShares":114694107,"shares":115708291,"eps":5.760439,"marketStatus":"交易中","marketStatusCode":2,"change":-0.26,"latestTime":"05-10 15:29:33 EDT","open":57.97,"high":57.97,"low":57.25,"amount":14766015.852882002,"amplitude":0.012511,"askPrice":57.3,"askSize":24,"bidPrice":57.28,"bidSize":85,"shortable":3,"etf":0,"ttmEps":5.760439,"exchange":"NYSE","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1715371200000},"adr":0,"listingDate":397195200000,"adjPreClose":57.55,"adrRate":0,"dividendRate":0.011171,"preHourTrading":{"tag":"盘前","latestPrice":57.55,"preClose":57.55,"latestTime":"08:03 EDT","volume":2,"amount":115.1,"timestamp":1715342585368},"postHourTrading":{"tag":"盘后","latestPrice":57.55,"preClose":57.55,"latestTime":"16:20 EDT","volume":44212,"amount":2544400.6,"timestamp":1715286000486},"volumeRatio":0.433874},"requestUrl":"/m/hq/s/CMC","defaultTab":"news","newsList":[{"id":"2430298296","title":"康龙化成：一季度CMC服务新签订单强劲增长40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430298296","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2430298296?lang=zh_cn&edition=full","pubTime":"2024-04-26 10:13","pubTimestamp":1714097588,"startTime":"0","endTime":"0","summary":"4月25日晚间，康龙化成(300759)披露2024年一季度报告，营业收入26.7亿元，微降1.95%，净利润2.3亿元，降幅约三成。针对一季度经营情况，公司表示，由于收入阶段性下降，再叠加其他因素所致，主要包括为了进一步实现规模效应，公司整合了上海、宁波、北京地区的实验室服务业务，关闭上海地区实验室带来的一次性亏损。其次，公司在建工程转为固定资产后的折旧导致费用也有所增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404263060800373.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404263060800373.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429849101","title":"天风证券：军民需求共振 国内CMC产业链有望进入高景气快速成长阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2429849101","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429849101?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:27","pubTimestamp":1713835648,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，天风证券发布研报称，华经情报网预测我国“十四五”期间内对陶瓷基复合材料的需求量将达100吨/年，且未来10年仅航发市场对CMC的需求将递增10倍。天风证券认为，伴随军用航空航天领域对超高音速、高推重比、耐高温防护等性能要求持续升温，以及国内国产商业航空航天领域对于高经济性、绿色化的推进，中国的CMC产业链有望进入高景气快速成长阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107305.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422976806","title":"云顶新耀发布2023年度全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2422976806","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2422976806?lang=zh_cn&edition=full","pubTime":"2024-03-28 07:18","pubTimestamp":1711581480,"startTime":"0","endTime":"0","summary":"上海2024年3月28日 /美通社/ -- 云顶新耀，一家专注于创新药及疫苗研发、临床开发、制造及商业化的生物制药公司，今日公布2023年度全年财务业绩报告及业务进展。澳门于2023年8月受理本公司关于耐赋康的新药上市许可申请。于2023年11月，韩国食品医药品安全部受理耐赋康新药上市许可申请，用于治疗成年IgA肾病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4372804_ZH72804_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422133959","title":"基石药业公布2023年年度业绩及公司近期业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2422133959","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2422133959?lang=zh_cn&edition=full","pubTime":"2024-03-27 22:00","pubTimestamp":1711548000,"startTime":"0","endTime":"0","summary":"2023年总收入为人民币4.638亿元，其中商业化收入人民币3.681亿元。稳健的财务状况，截至2023年12月31日现金储备为10.3亿人民币；年内亏损减少57%。预期两项申请将在2024年陆续获批。苏州2024年3月27日 /美通社/ -- 基石药业，一家专注于研究开发及商业化创新肿瘤免疫疗法及精准治疗药物的领先生物制药公司，今日公布其2023年年度业绩及近期业务亮点。业务摘要 截至2023年12月31日止年度及截至本公告日期，我们的产品管线及业务经营均已取得重大进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4372459_ZH72459_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421021359","title":"美国工商五金公司盘中异动 大幅拉升5.11%报58.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2421021359","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421021359?lang=zh_cn&edition=full","pubTime":"2024-03-22 00:29","pubTimestamp":1711038586,"startTime":"0","endTime":"0","summary":"北京时间2024年03月22日00时29分，美国工商五金公司股票出现异动，股价快速上涨5.11%。截至发稿，该股报58.87美元/股，成交量110.709万股，换手率0.95%，振幅5.86%。美国工商五金公司股票所在的钢铁行业中，整体涨幅为0.95%。其相关个股中，美国工商五金公司、正康国际、史尼泽钢铁涨幅较大，美国工商五金公司、美国钢铁、克里夫天然资源较为活跃，换手率分别为0.95%、0.53%、0.38%，振幅较大的相关个股有Inno Holdings Inc.、正康国际、Ascent Industries Co.，振幅分别为9.83%、7.39%、6.50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240322002946791c0aee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240322002946791c0aee&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421458060","title":"商业金属公司报告截至二月的季度业绩 - 盈利摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2421458060","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2421458060?lang=zh_cn&edition=full","pubTime":"2024-03-21 21:32","pubTimestamp":1711027966,"startTime":"0","endTime":"0","summary":"   * Commercial Metals Co   公布的截至二月份的季度调整后每股收益为88美分，低于去年同期的每股收益1.44美元。七位分析师对该季度的平均预期是每股收益 75 美分。华尔街预期为每股收益 64 美分至 86 美分。* 商业金属公司公布的本季度每股收益为 73 美分。* 公司报告的季度净收入为 8585 万美元。* Commercial Metals Co 的股价本季度上涨了 11.9%。3月21日 - 预测变化   * 在过去三个月中，分析师的平均盈利预测下降了约 18.2%。* 华尔街对 Commercial Metals Co 的 12 个月目标价中位数为 57.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421560010","title":"BUZZ-商业金属公司第二季度利润增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2421560010","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2421560010?lang=zh_cn&edition=full","pubTime":"2024-03-21 20:56","pubTimestamp":1711025808,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    3月21日 - ** 钢铁制造商商业金属  股价盘前上涨4%，报58.25美元 ** (link)，预计为75美分/时--伦敦证券交易所集团数据 ** 首席执行官 Peter Matt 表示：\"本季度钢铁产品利润率较废钢利润率呈上升趋势，这为继续保持强劲的利润率提供了坚实的基础。 ** 公司的钢铁产品发货量增至 694,000 吨，去年同期为 660,000 吨。 ** 然而，钢铁产品的每吨平均售价从 985 美元降至 905 美元。 ** 截至上一交易日收盘，股价年累计上涨约 12","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420734297","title":"云顶新耀宣布新加坡卫生科学局批准耐赋康®用于治疗成人原发性IgA肾病的新药上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2420734297","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2420734297?lang=zh_cn&edition=full","pubTime":"2024-03-20 09:00","pubTimestamp":1710896400,"startTime":"0","endTime":"0","summary":"上海2024年3月20日 /美通社/ -- 云顶新耀是一家专注于创新药及疫苗研发、临床开发、制造和商业化的生物制药公司，今日宣布新加坡卫生科学局已批准耐赋康用于治疗具有疾病进展风险的原发性IgA肾病成人患者。此次在新加坡获批，也即将造福东南亚地区急需对因治疗、延缓肾功能衰退的IgA 肾病患者。这项研究为期2年，包括9个月的耐赋康或安慰剂治疗期，随后是15个月的停药随访期。云顶新耀已打造多款疾病首创或者同类最佳的药物组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4366009_ZH66009_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420226764","title":"Commercial Metals Co   预计每股收益 73 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2420226764","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2420226764?lang=zh_cn&edition=full","pubTime":"2024-03-19 20:49","pubTimestamp":1710852562,"startTime":"0","endTime":"0","summary":"   * 商业金属公司   将于3月21日公布截至2024年2月29日的财报，预计季度收入将出现下降。* 根据LSEG的数据，6位分析师的平均预期显示，这家总部位于德克萨斯州欧文市的公司的营收将从去年同期的20.2亿美元降至18亿美元，降幅为10.8%。* LSEG 分析师对 Commercial Metals Co 的平均预期为每股收益 73 美分。* 华尔街对 Commercial Metals Co 的 12 个月目标价中位数为 57.00 美元，高于其上次收盘价 53.80 美元。3月19日 - 以前季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420464491","title":"云顶新耀宣布任命首席医学官及首席产品官以进一步加强管理团队","url":"https://stock-news.laohu8.com/highlight/detail?id=2420464491","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2420464491?lang=zh_cn&edition=full","pubTime":"2024-03-18 09:00","pubTimestamp":1710723600,"startTime":"0","endTime":"0","summary":"上海2024年3月18日 /美通社/ -- 云顶新耀是一家专注于创新药及疫苗研发、临床开发、制造和商业化的生物制药公司，今日宣布在实行\"以mRNA平台为基础的自主研发和产品成功商业化\"双轮驱动的重要阶段，公司任命曾庆雯女士为首席医学官和梁旭先生为首席产品官，进一步加强管理团队，提升研发、临床开发、医学事务和市场营销部门之间的战略整合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4363308_ZH63308_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2418328164","title":"云顶新耀合作伙伴Calliditas Therapeutics宣布美国FDA授予耐赋康®额外的七年孤儿药独占期","url":"https://stock-news.laohu8.com/highlight/detail?id=2418328164","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2418328164?lang=zh_cn&edition=full","pubTime":"2024-03-12 09:29","pubTimestamp":1710206940,"startTime":"0","endTime":"0","summary":"上海2024年3月12日 /美通社/ -- 云顶新耀的授权合作伙伴Calliditas Therapeutics AB宣布，基于耐赋康获得了新适应症的完全批准，美国食品药品监督管理局已授予其为期七年的额外孤儿药独占期至2030年12月。\" 韩国食品医药品安全部 于2022年11月授予 耐赋康孤儿药资格认定。2019年6月，云顶新耀与 Calliditas 签订独家授权许可协议，获得在大中华地区和新加坡开发以及商业化耐赋康的权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4358690_ZH58690_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2418820759","title":"云顶新耀宣布中国澳门药物监督管理局正式受理伊曲莫德（VELSIPITY®）用于治疗中重度活动性溃疡性结肠炎的新药上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2418820759","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2418820759?lang=zh_cn&edition=full","pubTime":"2024-03-11 09:00","pubTimestamp":1710118800,"startTime":"0","endTime":"0","summary":"--中国澳门有望成为伊曲莫德在云顶亚洲授权区内第一个获得新药上市批准的地区，并将通过粤港澳大湾区利好政策加快该药物在中国大陆的患者可及性-- 上海2024年3月11日 /美通社/ -- 云顶新耀是一家专注于创新药和疫苗开发、制造、商业化的生物制药公司，今日宣布中国澳门特别行政区药物监督管理局已正式受理伊曲莫德用于治疗中重度活动性溃疡性结肠炎成人患者的新药上市许可申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4357345_ZH57345_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417405855","title":"云顶新耀将于2024年3月28日公布2023年度全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2417405855","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2417405855?lang=zh_cn&edition=full","pubTime":"2024-03-06 08:52","pubTimestamp":1709686320,"startTime":"0","endTime":"0","summary":"上海2024年3月6日 /美通社/ -- 云顶新耀，一家专注于创新药及疫苗开发、制造及商业化的生物制药公司，今日宣布，公司将于北京时间2024年3月28日公布2023年度全年业绩及业务进展，并于当日举行英文及中文线上业绩会议。英文场次将于北京时间2024年3月28日上午9时举行；中文场次将于北京时间同日上午11时举行。云顶新耀已打造多款疾病首创或者同类最佳的药物组合，治疗领域包括肾科疾病、感染性和传染性疾病、自身免疫性疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4353965_ZH53965_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2414054861","title":"云顶新耀宣布中国国家药品监督管理局批准Zetomipzomib（泽托佐米）治疗狼疮性肾炎的新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2414054861","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2414054861?lang=zh_cn&edition=full","pubTime":"2024-02-27 07:01","pubTimestamp":1708988460,"startTime":"0","endTime":"0","summary":"Zetomipzomib是一款新型、同类首创、选择性免疫蛋白酶体抑制剂，用于治疗包括狼疮性肾炎、系统性红斑狼疮在内的一系列自身免疫性疾病。1期和2期临床试验的数据充分表明zetomipzomib在治疗严重、慢性自身免疫性疾病方面具有良好的安全性和耐受性特征。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4345589_ZH45589_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413456235","title":"云顶新耀授权合作伙伴Venatorx Pharmaceuticals宣布在《新英格兰医学杂志》上发表头孢吡肟-他尼硼巴坦3期临床研究的积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2413456235","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2413456235?lang=zh_cn&edition=full","pubTime":"2024-02-21 08:43","pubTimestamp":1708476180,"startTime":"0","endTime":"0","summary":"--头孢吡肟-他尼硼巴坦在复合疗效终点上优于美罗培南且复合疗效在后续随访访视期间维持-- 上海2024年2月21日 /美通社/ -- 云顶新耀的授权合作伙伴Venatorx Pharmaceuticals宣布《新英格兰医学杂志》发表了头孢吡肟-他尼硼巴坦治疗成人复杂性尿路感染患者的3期临床研究CERTAIN-1的积极结果。安全性数据 头孢吡肟-他尼硼巴坦的安全性特征与美罗培南一致。头孢吡肟-他尼硼巴坦组和美罗培南组的严重不良事件发生率分别为2.0%和1.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4341519_ZH41519_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2412944866","title":"云顶新耀宣布将终止与Providence Therapeutics公司的合作及授权许可协议，继续开发mRNA自研产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2412944866","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2412944866?lang=zh_cn&edition=full","pubTime":"2024-02-19 08:12","pubTimestamp":1708301520,"startTime":"0","endTime":"0","summary":"上海2024年2月19日 /美通社/ -- 云顶新耀是一家专注于创新药和疫苗开发、制造、商业化的生物制药公司，今日宣布将终止与Providence Therapeutics公司的合作及授权许可协议。云顶新耀将拥有Providence在协议终止之前向公司提供、转让的所有知识产权的全部权利，并将能够更加灵活地根据公司战略开发自研产品。2021年9月，云顶新耀与Providence达成全面战略合作协议，共同推进mRNA疫苗和疗法的开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4339504_ZH39504_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2409172002","title":"英国在线交易平台CMC Markets拟裁员约200人","url":"https://stock-news.laohu8.com/highlight/detail?id=2409172002","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2409172002?lang=zh_cn&edition=full","pubTime":"2024-02-05 16:33","pubTimestamp":1707122002,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英国在线交易平台CMC Markets周一表示，计划在全球裁员约200人，占其员工总数的17%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NGRhYzM3NGFmNjhkZjU2YzllYzhmYTA3NGMxMjcyMzM2MzUzOA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGRhYzM3NGFmNjhkZjU2YzllYzhmYTA3NGMxMjcyMzM2MzUzOA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"272677","is_publish_highlight":false,"gpt_icon":0},{"id":"2408955794","title":"抗体巨头再生元500万美元“抄底”，划算？FDA“黑框警告”，细胞疗法领域发生了什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2408955794","media":"医药经济报","top":-1,"share":"https://www.laohu8.com/m/news/2408955794?lang=zh_cn&edition=full","pubTime":"2024-01-31 22:07","pubTimestamp":1706710058,"startTime":"0","endTime":"0","summary":"抗体大分子药物巨头再生元“抄底”细胞疗法领域，引发市场关注。近年来，再生元开始通过外部合作和并购延伸新领域，此次并购就是其延伸细胞治疗领域的重要布局。根据协议，再生元将向2seventy bio支付500万美元的预付款，以获得2seventy实验药物项目的全部权利，并在交易产生的第一个项目首次获得市场批准后向其支付一笔里程碑付款。2023年8月，再生元宣布以1.09亿美元收购基因治疗公司Decibel Therapeutics，并于次月完成收购。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240131221143815eb02e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240131221143815eb02e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2405610109","title":"云顶新耀宣布2023年总收入预计达到人民币1.24亿至1.26亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2405610109","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2405610109?lang=zh_cn&edition=full","pubTime":"2024-01-22 07:41","pubTimestamp":1705880460,"startTime":"0","endTime":"0","summary":"上海2024年1月22日 /美通社/ -- 云顶新耀是一家专注于创新药和疫苗开发、制造、商业化的生物制药公司，今日宣布基于未经审计的初步计算，公司预计2023年的总收入达到人民币1.24亿至1.26亿元。该预期较2022年的人民币1280万元收入大幅增长，主要得益于创新型强效抗菌药物依嘉2023年7月在中国成功商业化上市以及全球首个对因治疗IgA肾病药物耐赋康于2023年12月在中国澳门商业化上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4316946_ZH16946_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2402531354","title":"BUZZ-商业金属公司增加现有股票回购计划后股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2402531354","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2402531354?lang=zh_cn&edition=full","pubTime":"2024-01-11 06:04","pubTimestamp":1704924246,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    1月10日 - ** 为建筑行业提供支持解决方案的 Commercial Metals   股价在延时交易中上涨 1.26% 至 50 美元 ** 公司宣布董事会已授权将公司现有的普通股回购计划增加5亿美元。** 这使该计划的总容量达到 8.5 亿美元 ** 公司表示，自 2021 年 10 月授权以来，已根据现有计划回购了约 3.1 亿美元的普通股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cmc.com","stockEarnings":[{"period":"1week","weight":0.0193},{"period":"1month","weight":-0.012},{"period":"3month","weight":0.0636},{"period":"6month","weight":0.2738},{"period":"1year","weight":0.3032},{"period":"ytd","weight":0.1501}],"compareEarnings":[{"period":"1week","weight":0.03},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0378},{"period":"6month","weight":0.1806},{"period":"1year","weight":0.2599},{"period":"ytd","weight":0.0944}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"美国工商五金公司于1946年在特拉华州成立。该公司是一个创新的解决方案提供商，帮助建立一个更强大、更安全和更可持续的世界。通过主要位于美国和中欧的广泛制造网络，该公司提供产品和技术，以满足全球建筑部门的关键加固需求。该公司的解决方案支持各种应用的建设，包括基础设施、非住宅、住宅、工业以及能源生产和传输。该公司的业务通过北美和欧洲这两个可报告的业务部门进行。","yearOnYearQuotes":[{"month":1,"riseRate":0.477273,"avgChangeRate":0.000354},{"month":2,"riseRate":0.590909,"avgChangeRate":0.019005},{"month":3,"riseRate":0.590909,"avgChangeRate":0.032004},{"month":4,"riseRate":0.577778,"avgChangeRate":0.012586},{"month":5,"riseRate":0.488889,"avgChangeRate":-0.003835},{"month":6,"riseRate":0.590909,"avgChangeRate":0.034974},{"month":7,"riseRate":0.590909,"avgChangeRate":0.017985},{"month":8,"riseRate":0.386364,"avgChangeRate":-0.02586},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.023918},{"month":10,"riseRate":0.522727,"avgChangeRate":0.017858},{"month":11,"riseRate":0.613636,"avgChangeRate":0.031894},{"month":12,"riseRate":0.522727,"avgChangeRate":0.015448}],"exchange":"NYSE","name":"美国工商五金公司","nameEN":"Commercial Metals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"美国工商五金公司(CMC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供美国工商五金公司(CMC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"美国工商五金公司,CMC,美国工商五金公司股票,美国工商五金公司股票老虎,美国工商五金公司股票老虎国际,美国工商五金公司行情,美国工商五金公司股票行情,美国工商五金公司股价,美国工商五金公司股市,美国工商五金公司股票价格,美国工商五金公司股票交易,美国工商五金公司股票购买,美国工商五金公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"美国工商五金公司(CMC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供美国工商五金公司(CMC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}